文献速递泌尿男性生殖肿瘤

多西他赛治疗转移性去势抵抗性前列腺癌进展后继续恩扎卢胺(PRESIDE):一项国际、随机、3b期研究

Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study.
PubMed 文献 · Lancet Oncol · 2022-10-18

PRESIDE是一项国际双盲随机3b期研究,入组经恩扎卢胺治疗后进展的mCRPC患者,随机接受多西他赛+泼尼松龙联合恩扎卢胺或安慰剂。恩扎卢胺组中位无进展生存期9.5个月 vs 安慰剂组8.3个月(HR 0.72,95%CI 0.53-0.96,p=0.027),达到主要终点。

要点

  • 恩扎卢胺联合多西他赛较单用多西他赛延长中位PFS(9.5 vs 8.3个月,HR 0.72)。
  • 3级不良事件最常见为中性粒细胞减少(17例 vs 12例)和乏力(10例 vs 6例)。
  • 严重不良事件恩扎卢胺组67例(49%)vs 安慰剂组52例(39%)。

核心结论

  • PRESIDE达到主要终点,恩扎卢胺联合多西他赛和雄激素剥夺治疗较单用多西他赛和雄激素剥夺治疗延迟了进展时间。

研究设计与样本

  • PRESIDE是一项两阶段、多国、双盲、随机、安慰剂对照3b期研究,在欧洲123个中心开展。
  • P1阶段688例患者入组并接受开放标签恩扎卢胺160 mg/日口服。
  • P2阶段271例患者按1:1随机分配至恩扎卢胺(n=136)或安慰剂(n=135),接受最多10个周期多西他赛75 mg/m²每3周静脉给药+泼尼松龙10 mg/日口服。

主要发现

  • 恩扎卢胺组中位无进展生存期9.5个月(95%CI 8.3-10.9)vs 安慰剂组8.3个月(95%CI 6.3-8.7),HR 0.72(95%CI 0.53-0.96),p=0.027。
  • 3级治疗中出现的不良事件最常见为中性粒细胞减少(恩扎卢胺组17例[13%] vs 安慰剂组12例[9%])和乏力(10例[7%] vs 6例[4%])。
  • 4级治疗中出现的不良事件最常见为中性粒细胞减少(恩扎卢胺组23例[17%] vs 安慰剂组28例[21%])。
  • 严重治疗中出现的不良事件:恩扎卢胺组67例(49%)vs 安慰剂组52例(39%)。
  • 恩扎卢胺组13例死亡中2例(15%)与多西他赛相关(感染性休克和血尿),安慰剂组7例死亡中1例(14%)与多西他赛相关(急性肾损伤)。

临床怎么用

  • 作者认为,对于单独恩扎卢胺治疗后进展的mCRPC患者,继续恩扎卢胺联合多西他赛和雄激素剥夺治疗可延迟进展时间,支持恩扎卢胺维持治疗可控制持续性雄激素依赖性克隆的假说。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although androgen deprivation therapy is typically given long-term for men with metastatic prostate cancer, second-generation hormone therapies are generally discontinued before the subsequent line of treatment. We aimed to evaluate the efficacy of continuing enzalutamide after progression in controlling metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel and prednisolone. METHODS: PRESIDE was a two-period, multinational, double-blind, randomised, placebo-controlled, phase 3b study done at 123 sites in Europe (in Austria, Belgium, Czech Republic, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, Turkey, and the UK). Patients were eligible for period 1 (P1) of the study if they had histologically confirmed prostate adenocarcinoma without neuroendocrine differentiation or small-cell features, serum testosterone concentrations of 1·73 nmol/L or less, and had progressed during androgen deprivation therapy with a luteinising hormone-releasing hormone agonist or antagonist or after bilateral orchiectomy. In P1, patients received open-label enzalutamide 160 mg per day orally. At week 13, patients were assessed for either radiographic or prostate-specific antigen (PSA) progression (25% or more increase and 2 ng/mL or more above nadir). Patients who showed any decline in PSA at week 13 and subsequently progressed (radiographic progression, PSA progression, or both) were screened and enrolled in period 2 (P2), during which eligible patients were treated with up to ten cycles of intravenous docetaxel 75 mg/m2 every 3 weeks and oral prednisolone 10 mg/day, and randomly assigned (1:1) to oral enzalutamide 160 mg/day or oral placebo. Patients were stratified by type of disease progression. The block size was four and the overall number of blocks was 400. Patients, investigators, and study organisers were masked to treatment assignment. The primary endpoint was progression-free survival analysed in all patients in P2. This trial is registered with ClinicalTrials.gov, NCT02288247, and is no longer recruiting. FINDINGS: Between Dec 1, 2014, and Feb 15, 2016, 816 patients were screened for P1 of the study. 688 patients were enrolled in P1 and 687 received open-label enzalutamide. In P2, 271 patients were randomly assigned at 73 sites to receive enzalutamide (n=136) or placebo (n=135). The data cutoff for analysis was April 30, 2020. Median progression-free survival with enzalutamide was 9·5 months (95% CI 8·3-10·9) versus 8·3 months (6·3-8·7) with placebo (hazard ratio 0·72 [95% CI 0·53-0·96]; p=0·027). The most common grade 3 treatment-emergent adverse events were neutropenia (17 [13%] of 136 patients in the enzalutamide group vs 12 [9%] of 135 patients in the placebo group) and asthenia (ten [7%] vs six [4%]). The most common grade 4 treatment-emergent adverse event in P2 was neutropenia (23 [17%] of 136 patients in the enzalutamide group vs 28 [21%] of 135 patients in the placebo group). Serious treatment-emergent adverse events were reported in 67 (49%) of 136 patients in the enzalutamide group and 52 (39%) of 135 patients in the placebo group. Two (15%) of 13 deaths in the enzalutamide group (caused by septic shock and haematuria) and one (14%) of seven deaths in the placebo group (caused by actue kidney injury) were associated with docetaxel. INTERPRETATION: PRESIDE met its primary endpoint and showed that continuing enzalutamide with docetaxel plus androgen deprivation therapy delayed time to progression compared with docetaxel plus androgen deprivation therapy alone, supporting the hypothesis that enzalutamide maintenance could control persistent androgen-dependent clones in men with mCRPC who progress after treatment with enzalutamide alone. FUNDING: Astellas Pharma and Pfizer.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Merseburger AS, Attard G, Åström L, et al. Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. Lancet Oncol. 2022. PMID: 36265504. doi:10.1016/S1470-2045(22)00560-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。